Payment overview · 2025
General Payments
$107.00
5 reported records · 5 companies
Healthcare provider profile · identity verified
Jorge Martinez, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MONTEBELLO, CA · NPI 1164475588
Verified facts
What the public records show
CMS Open Payments records show Jorge Martinez, M.D. received $107.00 in general payments during 2025 across 5 reported records.
Gilead Sciences, Inc. accounted for 27.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Glassia.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GLASSIA as an associated drug or biological on 7881 records involving 3215 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Glassia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $29.65 | 27.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $23.30 | 21.8% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $19.37 | 18.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.65 | 16.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.03 | 15.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $107.00 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GLASSIA glassia |
2025 | Glassia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GLASSIA open payments reported associated product |
CMS Open Payments — General Payments 7881 supporting records · 3215 recipient NPIs · example record 1223616286 |
Glassia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 328 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 284 | 76 |
| Losartan Potassium | Losartan Potassium | 266 | 71 |
| Metformin Hcl | Metformin Hcl | 216 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 206 | 59 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 189 | 31 |
| Levothyroxine Sodium | Levothyroxine Sodium | 173 | 41 |
| Gabapentin | Gabapentin | 145 | 39 |
| Omeprazole | Omeprazole | 138 | 45 |
| Jardiance | Empagliflozin | 127 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 121 | 41 |
| Lisinopril | Lisinopril | 114 | 36 |
| Ozempic | Semaglutide | 107 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 105 | 31 |
| Lorazepam | Lorazepam | 101 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 99 | 31 |
| Tramadol Hcl | Tramadol Hcl | 99 | 34 |
| Alendronate Sodium | Alendronate Sodium | 91 | 25 |
| Carvedilol | Carvedilol | 86 | 24 |
| Celecoxib | Celecoxib | 85 | 20 |
| Tradjenta | Linagliptin | 84 | 23 |
| Benazepril Hcl | Benazepril Hcl | 79 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 16 |
| Ketoconazole | Ketoconazole | 77 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 28 |
| Dexlansoprazole Dr | Dexlansoprazole | 71 | 18 |
| Furosemide | Furosemide | 70 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 64 | 19 |
| Ibuprofen | Ibuprofen | 62 | 29 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 62 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 61 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 12 |
| Meloxicam | Meloxicam | 57 | 20 |
| Trulicity | Dulaglutide | 57 | 12 |
| Vascepa | Icosapent Ethyl | 57 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | 16 |
| Pregabalin | Pregabalin | 56 | 16 |
| Alprazolam | Alprazolam | 52 | suppressed |
| Clonazepam | Clonazepam | 52 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 49 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 42 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 12 |
| Hydrocortisone | Hydrocortisone | 40 | suppressed |
| Lidocaine | Lidocaine | 40 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 19 |
| Trazodone Hcl | Trazodone Hcl | 39 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 38 | 12 |
| Levofloxacin | Levofloxacin | 38 | 31 |
| Repatha Pushtronex | Evolocumab | 36 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | suppressed |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Repatha Sureclick | Evolocumab | 34 | 11 |
| Sertraline Hcl | Sertraline Hcl | 34 | 12 |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Glimepiride | Glimepiride | 30 | suppressed |
| Glipizide | Glipizide | 30 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Allopurinol | Allopurinol | 28 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Simvastatin | Simvastatin | 27 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Ciclopirox | Ciclopirox | 21 | suppressed |
| Eliquis | Apixaban | 21 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 19 | 16 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 18 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Clotrimazole | Clotrimazole | 18 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 18 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Famotidine | Famotidine | 17 | 11 |
| Linzess | Linaclotide | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Cozaar | Losartan Potassium | 12 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 12 | suppressed |
| Glassia | Alpha-1-Proteinase Inhibitor | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $107.00 · 5 records | Gilead Sciences, Inc. | CAPLYTA, GLASSIA, Veozah | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Glassia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error